These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 26568144)
1. Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia. Genin MJ; Bueno AB; Agejas Francisco J; Manninen PR; Bocchinfuso WP; Montrose-Rafizadeh C; Cannady EA; Jones TM; Stille JR; Raddad E; Reidy C; Cox A; Michael MD; Michael LF J Med Chem; 2015 Dec; 58(24):9768-72. PubMed ID: 26568144 [TBL] [Abstract][Full Text] [Related]
2. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice. Hambruch E; Miyazaki-Anzai S; Hahn U; Matysik S; Boettcher A; Perović-Ottstadt S; Schlüter T; Kinzel O; Krol HD; Deuschle U; Burnet M; Levi M; Schmitz G; Miyazaki M; Kremoser C J Pharmacol Exp Ther; 2012 Dec; 343(3):556-67. PubMed ID: 22918042 [TBL] [Abstract][Full Text] [Related]
3. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Evans MJ; Mahaney PE; Borges-Marcucci L; Lai K; Wang S; Krueger JA; Gardell SJ; Huard C; Martinez R; Vlasuk GP; Harnish DC Am J Physiol Gastrointest Liver Physiol; 2009 Mar; 296(3):G543-52. PubMed ID: 19136377 [TBL] [Abstract][Full Text] [Related]
4. Improvement of physiochemical properties of the tetrahydroazepinoindole series of farnesoid X receptor (FXR) agonists: beneficial modulation of lipids in primates. Lundquist JT; Harnish DC; Kim CY; Mehlmann JF; Unwalla RJ; Phipps KM; Crawley ML; Commons T; Green DM; Xu W; Hum WT; Eta JE; Feingold I; Patel V; Evans MJ; Lai K; Borges-Marcucci L; Mahaney PE; Wrobel JE J Med Chem; 2010 Feb; 53(4):1774-87. PubMed ID: 20095622 [TBL] [Abstract][Full Text] [Related]
5. Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes. Richter HG; Benson GM; Blum D; Chaput E; Feng S; Gardes C; Grether U; Hartman P; Kuhn B; Martin RE; Plancher JM; Rudolph MG; Schuler F; Taylor S; Bleicher KH Bioorg Med Chem Lett; 2011 Jan; 21(1):191-4. PubMed ID: 21134747 [TBL] [Abstract][Full Text] [Related]
6. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). Flatt B; Martin R; Wang TL; Mahaney P; Murphy B; Gu XH; Foster P; Li J; Pircher P; Petrowski M; Schulman I; Westin S; Wrobel J; Yan G; Bischoff E; Daige C; Mohan R J Med Chem; 2009 Feb; 52(4):904-7. PubMed ID: 19159286 [TBL] [Abstract][Full Text] [Related]
7. Liver X receptor and farnesoid X receptor as therapeutic targets. Rader DJ Am J Cardiol; 2007 Dec; 100(11 A):n15-9. PubMed ID: 18047847 [TBL] [Abstract][Full Text] [Related]
8. Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: Understanding and improving key determinants of pharmacological properties. Kinzel O; Steeneck C; Schlüter T; Schulz A; Gege C; Hahn U; Hambruch E; Hornberger M; Spalwisz A; Frick K; Perović-Ottstadt S; Deuschle U; Burnet M; Kremoser C Bioorg Med Chem Lett; 2016 Aug; 26(15):3746-53. PubMed ID: 27268696 [TBL] [Abstract][Full Text] [Related]
9. Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH). Tully DC; Rucker PV; Chianelli D; Williams J; Vidal A; Alper PB; Mutnick D; Bursulaya B; Schmeits J; Wu X; Bao D; Zoll J; Kim Y; Groessl T; McNamara P; Seidel HM; Molteni V; Liu B; Phimister A; Joseph SB; Laffitte B J Med Chem; 2017 Dec; 60(24):9960-9973. PubMed ID: 29148806 [TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, and Biological Evaluation of Novel Nonsteroidal Farnesoid X Receptor (FXR) Antagonists: Molecular Basis of FXR Antagonism. Huang H; Si P; Wang L; Xu Y; Xu X; Zhu J; Jiang H; Li W; Chen L; Li J ChemMedChem; 2015 Jul; 10(7):1184-99. PubMed ID: 25982493 [TBL] [Abstract][Full Text] [Related]
11. Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064. Bass JY; Caldwell RD; Caravella JA; Chen L; Creech KL; Deaton DN; Madauss KP; Marr HB; McFadyen RB; Miller AB; Parks DJ; Todd D; Williams SP; Wisely GB Bioorg Med Chem Lett; 2009 Jun; 19(11):2969-73. PubMed ID: 19410460 [TBL] [Abstract][Full Text] [Related]
12. Novel heterocyclic scaffolds of GW4064 as farnesoid X receptor agonists. Smalley TL; Boggs S; Caravella JA; Chen L; Creech KL; Deaton DN; Kaldor I; Parks DJ Bioorg Med Chem Lett; 2015 Jan; 25(2):280-4. PubMed ID: 25499883 [TBL] [Abstract][Full Text] [Related]
13. Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties. Richter HG; Benson GM; Bleicher KH; Blum D; Chaput E; Clemann N; Feng S; Gardes C; Grether U; Hartman P; Kuhn B; Martin RE; Plancher JM; Rudolph MG; Schuler F; Taylor S Bioorg Med Chem Lett; 2011 Feb; 21(4):1134-40. PubMed ID: 21269824 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists. Abel U; Schlüter T; Schulz A; Hambruch E; Steeneck C; Hornberger M; Hoffmann T; Perović-Ottstadt S; Kinzel O; Burnet M; Deuschle U; Kremoser C Bioorg Med Chem Lett; 2010 Aug; 20(16):4911-7. PubMed ID: 20638278 [TBL] [Abstract][Full Text] [Related]
15. Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties. Flesch D; Gabler M; Lill A; Gomez RC; Steri R; Schneider G; Stark H; Schubert-Zsilavecz M; Merk D Bioorg Med Chem; 2015 Jul; 23(13):3490-8. PubMed ID: 25934227 [TBL] [Abstract][Full Text] [Related]
16. Farnesoid X receptor antagonist exacerbates dyslipidemia in mice. Amano Y; Yamakawa H; Yonemori K; Shimada M; Tozawa R Pharmacol Rep; 2018 Feb; 70(1):172-177. PubMed ID: 29367104 [TBL] [Abstract][Full Text] [Related]
18. Cardiovascular protective effects of Casearia sylvestris Swartz in Swiss and C57BL/6 LDLr-null mice undergoing high fat diet. Frediani Brant NM; Mourão Gasparotto F; de Oliveira Araújo V; Christian Maraschin J; Lima Ribeiro Rde C; Botelho Lourenço EL; Cardozo Junior EL; Gasparotto Junior A J Ethnopharmacol; 2014 Jun; 154(2):419-27. PubMed ID: 24747027 [TBL] [Abstract][Full Text] [Related]
19. Structure-guided modification of isoxazole-type FXR agonists: Identification of a potent and orally bioavailable FXR modulator. Luo G; Lin X; Li Z; Xiao M; Li X; Zhang D; Xiang H Eur J Med Chem; 2021 Jan; 209():112910. PubMed ID: 33049605 [TBL] [Abstract][Full Text] [Related]
20. Antidyslipidemic potential of a novel farnesoid X receptor antagonist in a hamster model of dyslipidemia: Comparative studies of other nonstatin agents. Shinozawa E; Amano Y; Yamakawa H; Haba M; Shimada M; Tozawa R Pharmacol Res Perspect; 2018 Apr; 6(2):e00390. PubMed ID: 29541476 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]